Why carry out this study?

H. pylori eradication therapy requires a complex prescribing schedule combining clarithromycin, amoxicillin, and a proton-pump inhibitor or a potassium-competitive acid blocker such as vonoprazan

To reduce the burden of complex prescribing and increase adherence, a vonoprazan triple-drug blister pack comprising all three medications was launched in June 2016

This study aimed to assess the impact of the combination blister pack on eradication success rate in Japan immediately after launch through analysis of a large administrative claims database

What was learned from the study?

The success rate of clarithromycin triple therapy increased by 2.44% after launch of the vonoprazan triple-drug blister pack. The proportion of vonoprazan use and proportion of combination blister pack use increased by 12.7% and 29.2%, respectively

Launch of the vonoprazan triple-drug blister pack had a significant impact on the success rate of clarithromycin triple therapy, with greater proportions of vonoprazan and combination blister pack use. Introducing an easy-to-use formulation may be effective in changing prescribing practice and subsequent patient outcomes